BioNTech SE

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 5.02%152.060.0%$1895.16m
NVAXNovavax, Inc. -2.31%234.4092.9%$1463.22m
OCGNOcugen, Inc. -8.85%8.140.0%$881.78m
AMGNAmgen, Inc. -0.82%228.121.3%$593.38m
ILMNIllumina, Inc. -3.13%446.623.5%$552.20m
REGNRegeneron Pharmaceuticals, Inc. -0.72%455.312.7%$529.11m
VRTXVertex Pharmaceuticals, Inc. -1.66%213.431.9%$510.26m
GILDGilead Sciences, Inc. -1.01%63.071.0%$495.36m
BNGOBioNano Genomics, Inc. -6.89%10.420.0%$450.76m
ALXNAlexion Pharmaceuticals, Inc. -0.15%154.262.0%$390.82m
BIIBBiogen, Inc. -1.39%278.821.7%$379.39m
CRSPCRISPR Therapeutics AG -2.88%129.680.6%$309.70m
SRNESorrento Therapeutics, Inc. -3.37%10.601.3%$256.96m
EXASEXACT Sciences Corp. -2.87%130.9618.4%$252.03m
VXRTVaxart, Inc. 7.49%7.890.0%$239.56m

Company Profile

BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. It exploits an array of discovery and therapeutic drug platforms for the development of novel biopharmaceuticals. The company's portfolio of infectious disease and oncology product candidates include FixVac, iNeST (Individualized Neoantigen Specific Immunotherapy), Intratumoral Immunotherapies, RiboMabs, RiboCytokines, CAR T Cell Platform, T Cell Receptor(TCR), Checkpoint Immunomodulator, Targeted Cancer Antibodies, and Small Molecule Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.